Risk score, tumor size, CDKN2A mutation, BRCA1 mutation, N stage, residual tumor, history of radiation therapy, targeted molecular therapy, and chemotherapy were identified to be significantly related to OS of PDAC in univariate Cox analysis, with p < 0.05 (Table 4). The gene discussed is CDKN2A; the disease is neoplasm.